RT Journal Article
SR Electronic
T1 Chronic post-COVID neuropsychiatric symptoms (PCNPS) persisting beyond one year from being infected during the ‘Omicron wave’
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.01.24312691
DO 10.1101/2024.09.01.24312691
A1 Chau, Steven Wai Ho
A1 Chue, Timothy Mitchell
A1 Lam, Tsz Ching
A1 Lai, Yee Lok
A1 Chan, Rachel Ngan Yin
A1 Wong, Paul WC
A1 Li, Shirley Xin
A1 Liu, Yaping
A1 Chan, Joey Wing Yan
A1 Chan, Paul Kay-sheung
A1 Lai, Christopher Koon-Chi
A1 Leung, Thomas WH
A1 Wing, Yun Kwok
YR 2024
UL http://medrxiv.org/content/early/2024/09/03/2024.09.01.24312691.abstract
AB The heterogeneity of chronic post-COVID neuropsychiatric symptoms (PCNPS), especially after infection by the Omicron strain, has not been adequately explored. Our pre-registered hypotheses are 1. chronic PCNPS in patients infected with SARS-CoV-2 over a year ago during the ‘Omicron wave’ showed a similar clustering pattern with symptoms in patients infected with pre-Omicron strain; 2. these chronic PCNPS are associated with a) clinical risk factors, such as, severity of the acute infection; b) socioeconomic status e.g., level of deprivation; and c) pre-infection vaccination status. We assessed 1205 subjects using app-based questionnaires and cognitive tasks. Partial network analysis on chronic PCNPS in this cohort produced two major symptom clusters (cognitive complaint-fatigue cluster and anxiety-depression symptoms cluster) and a minor headache-dizziness symptoms cluster, like our pre-Omicron cohort. Subjects with high number of symptoms (4 or more) can be further grouped into two distinct phenotypes: a cognitive complaint-fatigue predominant phenotype (CF) and another with symptoms across multiple clusters (AD-CF). Multiple logistic regression showed that both phenotypes are predicted by the level of deprivation before infection (adjusted p-value for CF and AD-CF = 0.025 and 0.0054 respectively). While the severity of acute COVID (adjusted p-value = 0.023) and the number of pre-existing medical conditions predict only the CF phenotypes (adjusted p-value = 0.003), past suicidal ideas predict the AD-CF phenotype (adjusted p-value < 0.001). Pre-infection vaccination status did not predict either phenotype. Our finding suggests that we should recognize the heterogeneity under the umbrella of chronic PCNPS, and a holistic bio-psycho-social approach is essential in understanding them.Competing Interest StatementDeclaration of Interest: JWYC received personal fees from Eisai Co., Ltd and travel support from Lundbeck HK limited for overseas conference. CKCL received honoraria for lectures from GSK, and support for attending meetings from Pfizer. YKW received personal fees from Eisai Co., Ltd., for delivering a lecture, and sponsorship from Lundbeck HK Ltd and Aculys Pharma, Inc. Funding StatementThis study was funded by the Research Grant Council (SWHC, grant number C4061-21G) and the Health Bureau, Hong Kong SAR (RHYC and YKW, grant number COVID1903002). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Clinical Research Ethics Committee of the Joint Chinese University of Hong Kong (CUHK) Hospital Authority New Territories East Cluster (NTEC) (Ref. no.: 2022.362) gave ethical approval for this work. The Central Institution Review Board of the Hospital Authority gave ethical approval for this work (Ref. no.: CIRB-2022-006-1).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study will be openly available after the paper is published